11 Jan 2019 Research

Lymphoma: Understanding relapse and treatment resistance

What is this research looking at?

Our immune system is remarkable. It is made up of many different types of immune cells that work together to protect the body from infection by pathogens such as bacteria, viruses and parasites.

We are investigating what happens when a certain type of cell in the immune system, known as B cells, starts growing out of control and develops into blood cancers such as leukaemia, lymphoma and myeloma.

We want to know what happens when B cells mature normally from precursor cells in the bone marrow and discover what has gone wrong when they turn into cancer cells instead.

Considerable success has been achieved in the treatment of lymphoma. However, a significant unmet need remains: roughly 40% of patients either do not respond to treatment or the condition recurs after treatment. Currently, our ability to predict which patients will fail treatment is poor.

By taking a detailed look at B cells as they develop and specialise, we can spot small groups of dangerous cells that are particularly likely to turn into cancer and identify the genetic faults that drive B cells to grow out of control.

We are using our knowledge to create new models for the development of B cells and blood cancers in the lab, so we can find new ways to treat or even prevent these deadly diseases.

Our research uses a model of lymphoma to test the response to treatments and development of resistance. A main advantage of the model is that we can interrogate these questions on a well-defined scenario and can perform iterative tests and predictions. Further, the model generated in this project will allow initial testing of novel treatments.

What could this mean for people with leukaemia?

This research could inform the medical decision of when to use combination and novel therapies for patients with a higher probability of developing resistance to standard treatment, alongside bringing safer treatments to patients.

Official project title: Development of a model system to study diffuse large B cell lymphoma clonal evolution

Related posts

Leukaemia UK awarded Christmas Grant to support life-saving research

3 February 2022

Leukaemia UK awarded Christmas Grant to support life-saving research

Leukaemia UK are delighted to have been awarded a special Christmas Grant from Kusuma Trust UK.

Emerging leaders accolade for former Leukaemia UK John Goldman Fellows

20 October 2023

Emerging leaders accolade for former Leukaemia UK John Goldman Fellows

Former Leukaemia UK John Goldman Fellows, Dr Matthew Blunt, University of Southampton and Dr Konstantinos Tzelepis, University of Cambridge have been recognised as ‘Emerging Leaders in Leukaemia’ by the major…

Leukaemia UK bolsters research and advocacy team, in support of ambitious strategy to accelerate progress in the diagnosis, treatment, and care of leukaemia

30 January 2024

Leukaemia UK bolsters research and advocacy team, in support of ambitious strategy to accelerate progress in the diagnosis, treatment, and care of leukaemia

Leukaemia UK is pleased to announce Dr Simon Ridley as the new Director of Research and Advocacy and Dr Georgia Papacleovoulou as the organisation’s first ever Head of Policy and…

One Cancer Voice 10-Year Cancer Plan Consensus Statement

30 March 2022

One Cancer Voice 10-Year Cancer Plan Consensus Statement

We have joined with 53 cancer charities to speak with One Cancer Voice and publish 10 tests that the Government’s new 10-year Cancer Plan must meet if it is to be successful.